Santen releases long-term data on PRESERFLO® MicroShunt and Endothelial Cell Density loss


The pharmaceutical company will present study results at the World Glaucoma Congress.

An auditorium full of people in a lecture hall, paying attention to an on-stage presentation. Image credit: ©Gennady Danilkin –

Santen will present data on 2-year and 4-year outcomes, as well as figures from a 3-year cohort. Image credit: ©Gennady Danilkin –

In a news release, ophthalmology specialist Santen previewed long-term data on the PRESERFLO® MicroShunt.1 The data will be presented in poster format at the World Glaucoma Congress (WGC), held in Rome, Italy, from 28 June to 1 July. Santen, headquartered in Osaka, Japan, will also host two symposia at the WGC.

According to the news release, data from an ongoing Open-Label Extension Study on PRESERFLO® MicroShunt (INN005) reflects 4-year outcomes in Endothelial Cell Density (ECD) loss.1 “The risk of Endothelial Cell Density (ECD) loss has long been a concern of surgeons implanting glaucoma stents,” said Professor Henny Beckers, University Eye Clinic, Maastricht, Netherlands. “This data 4 years on from PRESERFLO® MicroShunt surgery is reassuring for both surgeons and patients about the longer-term implications of their treatment.”1

Data shared ahead of the WGC shows that “ECD loss at 4 years post-implantation is similar in patients implanted with PRESERFLO® MicroShunt and those who received trabeculectomy.” At month 48, “the mean percentage ECD loss from screening was -16.2 and -13.9, respectively (p=0.498).”1 Santen’s posters will display data from an ongoing study with 4-year data points (P-437), as well as 2-year data from the INN005 study (P-433).

Further, Professor Ike Ahmed, Department of Ophthalmology, John A. Moran Eye Center, University of Utah, will share findings from a recently-published study. Professor Ahmed’s presentation will include 3-year retrospective data from “a large cohort of PRESERFLO® MicroShunt patients with mitomycin C (MMC) (n=135).” The news release indicates 59.4% of patients in that group were medication-free after three years.1

Ioana Grobeiu, Head of Medical Affairs at Santen, said, “We are delighted to bring clinicians up to date on the latest evidence for our therapies through a range of symposia and poster presentations and to discuss the implications for patient care.”


  1. New data on PRESERFLO® MicroShunt presented by Santen at World Glaucoma Congress. News release. Mearns & Pike Limited, June 28, 2023.
Related Videos
Josefina Botta, MD, MSc, at ASCRS 2024
Dr Nir Shoham Hazon, Director, Miramichi EyeNB Centre of Excellence, New Brunswick, Canada
J. Morgan Micheletti, MD, speaks at the 2024 ASCRS meeting
Dr William Wiley of Cleveland Eye Clinic, Northeast Ohio
© 2024 MJH Life Sciences

All rights reserved.